Drug Trial Radar · NCT05917938
A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function
Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
Jul 4, 2023
Primary completion
Dec 16, 2024
Study completion Dec 16, 2024
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jun 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study medicine NNC0194-0499 is under development for non-alcoholic fatty liver disease (NAFLD) including non-alcoholic steatohepatitis (NASH). All participants will receive a single dose of 30 milligram (mg) of the study medicine. The study medicine will be given in the form of an injection of 0.6 millilitres in a skinfold of the thigh (subcutaneous). The study will last for up to 64 days. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period. Women who are able to become pregnant must use highly effective contraception and will be counselled on the use of contraception. Participants with impaired liver function will undergo an ultrasound of the belly and measurement of brain activity.
Conditions
- Hepatic Impairment
- Healthy Volunteers
Interventions
NNC0194-0499Drug
NNC0194-0499 will be administered subcutaneously in a skinfold in the thigh in the form of a solution for injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC0-∞, Single Dose, NNC0194-0499: the area under the NNC0194-0499 serum concentration-time curve from time 0 to infinity after a single doseTime frame: From 0 hours (Day 1) until end of study visit (Day 36)
Locations
5 sites in 3 countries. Site status is shown where the registry gives one.
APEX Research
München, Germany
Uniwersyteckie Centrum Kliniczne (UCK)
Gdansk, Poland
Cardiomedicum Sp. z o.o.
Krakow, Poland
Summit Clinical Research s.r.o.
Bratislava, Slovakia
Summit Clinical Research s.r.o.
Malacky, Slovakia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.